Assessing the Impact of Timing and Coverage of United States COVID-19 Vaccination Campaigns: A Multi-Model Approach

Read full text
Authors: Anjalika A Nande, Sophie L. Larsen, James Turtle, Jessica T. Davis, Shraddha Ramdas Bandekar, Bryan Leroy Lewis, Shi Chen, Lucie Contamin, Sung-mok Jung, Emily Howerton, Katriona Shea, Clara Bay
+23 more M. Ben-Nun, Kaiming Bi, Anass Bouchnita, J. D.Z. Chen, Matteo Chinazzi, Spencer J. Fox, Alison L. Hill, Harry Hochheiser, Joseph Chadi Lemaitre, Sara L. Loo, MADHAV V. MARATHE, Lauren Ancel Meyers, Claire Pearson, Przemyslaw Jerzy Porebski, Emily Przykucki, Claire P. Smith, Srinivasan Venkatramanan, Alessandro Vespignani, Timothy Willard, Katie Yan, Cecile G. Viboud, Justin Lessler, Shaun Truelove
Cited by: 1
References: 26

Abstract

Six years after its emergence, SARS-CoV-2 continues to have a substantial burden, however, the impact of vaccination and the optimal timing of its rollout remain uncertain. To explore these uncertainties, the US Scenario Modeling Hub convened its 19th round of ensemble projections for COVID-19 hospitalizations and deaths in the United States. Eight teams provided outcomes for each US state and nationally from April 2025 to April 2026 under five scenarios regarding vaccine recommendations and timing. We assessed recommendations with two eligibility scenarios (high-risk individuals only and all-eligible) and two timing scenarios (classic start: mid-August, earlier start: late June). These were crossed to create four scenarios and were compared against a counterfactual scenario with no vaccination. We found that compared to no vaccination, our ensemble projections estimated 90,000 (95% PI 53,000-126,000) hospitalizations averted in the high-risk and classic timing scenario across the US. Expanding coverage averted an additional 26,000 (95% PI 14,000-39,000) hospitalizations, which when coupled with earlier vaccination timing further reduced national hospitalizations by 15,000 (95% PI -3,000-33,000). These findings estimate significant benefits from a broad all-eligible vaccination recommendation, and suggest an additional benefit is likely to be gained from an earlier vaccination campaign.

Fields of Study & Subjects

COVID-19 epidemiological studies SARS-CoV-2 and COVID-19 Research Vaccine Coverage and Hesitancy

Publication details

Journal / source
medRxiv
Publisher
openRxiv
Publication date
8 April 2026
Language
EN
Document type
Preprint